Last updated: February 20, 2026
What is the Drug Identified by NDC 68968-0205?
NDC 68968-0205 refers to Ocrevus (ocrelizumab), a monoclonal antibody indicated for the treatment of multiple sclerosis (MS), including relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). It was approved by the FDA in March 2017.
Market Size and Growth Drivers
Current Market Size
- The global multiple sclerosis market was valued at approximately USD 22.6 billion in 2022.
- The North American MS market accounted for about 45% of this total.
- Ocrevus held an estimated 40% share of US disease-modifying therapies (DMTs) for MS as of 2022, making it the leading treatment.
Key Growth Factors
- Increasing prevalence of MS: Approximately 2.8 million people worldwide suffer from MS, with US counts surpassing 900,000.
- Diagnosis trends: Enhanced awareness and improved diagnostic capabilities lead to earlier detection.
- Treatment paradigm shifts: Physicians favor high-efficacy, biologic DMTs, especially for aggressive or rapidly progressing MS.
Competitive Landscape
| Product Name |
Market Share (2022) |
Administration |
Indications |
Pricing (per infusion) |
| Ocrevus |
40% |
IV |
RRMS, PPMS |
USD 6,000–8,000 |
| Tecfidera |
25% |
Oral |
RRMS |
USD 65,000 annually |
| Tysabri |
10% |
IV |
RRMS, Crohn's disease |
USD 7,900 per infusion |
| Mavenclad |
8% |
Oral |
RRMS, active forms |
USD 52,000 annually |
| Others |
17% |
Variable |
Various MS subtypes |
Variable |
Revenue Projections
- US MS biologics market is forecasted to grow at 6% CAGR from USD 9.1 billion in 2022 to USD 12 billion by 2027.
- Ocrevus is expected to maintain a leading position with a 38-42% market share due to its efficacy profile.
Pricing Trends and Projections
Current Pricing Dynamics
- Average wholesale acquisition cost (AWAC) for Ocrevus ranges between USD 6,000 and USD 8,000 per infusion.
- Dosing: 600 mg administered every six months; typically, two 300 mg infusions per dose.
- Annual treatment cost estimates range from USD 36,000 to USD 48,000, depending on dosing adjustments and administration fees.
Price Trends
- Prices of biologics like Ocrevus have plateaued over the past three years, with slight increases averaging 2–3% annually.
- Payers impose stricter utilization controls and step therapy, limiting price increases.
Future Price Projections
| Year |
Estimated Average Price per Infusion |
Rationale |
| 2023 |
USD 8,000 |
Current level, with minimal inflation |
| 2025 |
USD 8,200 |
Slight increase due to inflation, market conditions |
| 2030 |
USD 8,500 |
Possible modest increase; biosimilar competition delayed |
Note: Biosimilars for ocrelizumab are under development, which may influence market prices post-2030 but are unlikely to impact pricing immediately within the next five years.
Competitive and Regulatory Factors Influencing Market
- Biosimilar development: Several companies, including Samsung Bioepis and Coherus BioSciences, are developing biosimilars expected to enter the market around 2030.
- Regulatory landscape: The FDA's encouragement of biosimilar approvals may put downward pressure on prices.
- Therapeutic positioning: Ocrevus's efficacy and safety profile sustain its market dominance despite potential biosimilar entrants.
Key Takeaways
- The US MS biologics market is growing steadily due to rising prevalence and treatment complexity.
- Ocrevus currently commands a significant market share with annual prices around USD 36,000–48,000.
- Price projections suggest stability through 2025, with incremental increases expected. Biosimilar entry around 2030 could reduce prices.
- Competitive pressure and payer restrictions limit pricing flexibility.
FAQs
What factors could cause Ocrevus's price to decrease?
Introduction of biosimilars, increased payer negotiations, and market saturation could drive costs downward. Regulatory or policy changes favoring biosimilar adoption will also influence pricing.
Will the demand for Ocrevus grow beyond 2025?
Yes. The MS population, especially with earlier diagnosis and expanded indications like PPMS, will support sustained demand.
How does Ocrevus compare to other MS treatments in price and efficacy?
It offers high efficacy with infrequent dosing, justifying higher costs compared to oral DMTs like Tecfidera. Cost-effectiveness analyses favor Ocrevus in patients needing high-efficacy therapies.
Are there upcoming regulations that could impact the MS drug market?
The FDA's continued support for biosimilars and value-based pricing models may influence future pricing and market shares.
When are biosimilars for ocrelizumab expected to reach the market?
Potentially around 2030, based on current development timelines. Market entry could lead to significant pricing revisions.
Citations
[1] IQVIA. (2023). MS Market Data Report.
[2] EvaluatePharma. (2022). Global Oncology & Immunology Market Forecast.
[3] U.S. Food and Drug Administration. (2017). Ocrevus (ocrelizumab) approval documentation.
[4] GoodRx. (2023). Average wholesale drug prices and trends.
[5] MarketsandMarkets. (2022). Biologic Therapeutics Market Trends.
